PATTERNS OF ANTIHYPERTENSIVE MONO THERAPY IN HYPERTENSIVE TYPE-2 DIABETICS ON GLIMEPIRIDE METFORMIN COMBINATION
Beere Nagaraju
Department of Pharmacology, Visveswarapura Institute of Pharmaceutical Sciences (under RGUHS), KIMS Hospital and Research Centre (Mentor Institute), Bengaluru 560070, India.
Anil Kumar KV
Department of Pharmacology, Visveswarapura Institute of Pharmaceutical Sciences (under RGUHS), KIMS Hospital and Research Centre (Mentor Institute), Bengaluru 560070, India.
Ramachandra Setty S
Professor & Head, Department of Pharmacology, Government College of Pharmacy, Bengaluru-560027, India.
Ravindran M
Chief Medical Superintendent, South Western Railway Divisional Hospital, Bengaluru 560023, India.
Shekar HS
Department of Pharmacy Practice, Visveswarapura Institute of Pharmaceutical Sciences, KIMS Hospital and Research Centre, Bengaluru 560002, India.
Sreemantula Satyanarayana
Director, Avanthi Institute of Pharmaceutical Sciences (under Andhra University), Cherukupalli, Vizianagaram-500027, AP, India.
Padmavathi GV
Department of Pediatric Nursing, KTG College of Nursing, Bengaluru-560091, India.
Hypertension is extremely prevalent in patients with diabetes and one of the major risk factors for cardiovascular morbidity and its prevalence is high in most of the countries in the world. Limited data exist on patterns of antihypertensive use in Type-2 Diabetics consistent to evidence-based practice guidelines. Objective of the study is to evaluate patterns of antihypertensive monotherapy in Type-2 diabetics on Glimepiride Metformin combination. A total of 133 prescriptions randomly selected from October to November 2015 were used in the study. Prescription details were recorded and analyzed accordingly. The study revealed that 61% of the patients were males and 39% of the patients were females. Most of the patients were in the age group of 51-65 years (44.36%) followed by age group of 36-50 years (37.5%). Among the Type-2 diabetics on Glimepiride Metformin (GM) combination, the antihypertensive drugs were prescribed as monotherapy highly are Angiotensin Receptor Blockers (ARBs) (32.35%) followed by Beta Blockers (22.55%), Angiotensin Converting Enzyme (ACE) Inhibitors (21.05%) and Calcium Channel Blockers (18.80%). The pattern of drug therapy should be based on severity of disease condition, associated co-morbid conditions and currently available evidences in order to promote the quality use of drugs, as the present patterns of anti-hypertensive therapy were generally consistent with evidence-based practice guidelines and showed the areas of improvement include increasing ARBs use
6 , 1 , 2016
19 - 23